StreetInsider.com News Articles

Royalty Pharma acquires royalty stake in AstraZeneca's cliramitug

Wed, 22 Jul 2026 07:05:09 -0400

Royalty Pharma plc (Nasdaq: RPRX) has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million paid upfront, according to a press release statement.

Cliramitug is a Phase 3 antibody candidate targeting TTR amyloidosis with cardiomyopathy (ATTR-CM), a disease caused by misfolded proteins that accumulate in the heart. Unlike currently approved therapies that slow disease progression by preventing further accumulation, cliramitug is designed to remove existing amyloid deposits. Phase 3 trial results from the DepleTTR-CM study are expected in 2028, based on AstraZeneca guidance.

Under the transaction terms, Royalty Pharma will receive a 3%

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

Wed, 22 Jul 2026 07:05:00 -0400

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront.

Cliramitug is a Phase 3 first-in-class TTR-fibril-depleting antibody designed to remove amyloid deposits in patients with TTR amyloidosis with cardiomyopathy (ATTR-CM), a progressive, degenerative and fatal disease caused by misfolded proteins that accumulate in the heart. Currently approved therapies for ATTR-CM slow disease progression by preventing ATTR accumulation but do not target amyloid already accumulated in the heart. Cliramitug is

Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

Wed, 22 Jul 2026 07:05:00 -0400

Royalty Pharma plc (RPRX) Declares $0.235 Quarterly Dividend; 1.6% Yield

Fri, 17 Jul 2026 16:17:02 -0400

Royalty Pharma plc (NASDAQ: RPRX) declared a quarterly dividend of $0.235 per share, or $0.94 annualized.

The dividend will be payable on September 10, 2026, to stockholders of record on August 14, 2026, with an ex-dividend date of August 13, 2026.

The annual yield on the dividend is 1.6 percent.

For a dividend history and other dividend-related data on Royalty Pharma plc (RPRX) click here.

Royalty Pharma declares third quarter 2026 dividend

Fri, 17 Jul 2026 16:15:00 -0400

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share.

The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026.

About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits

Royalty Pharma declares third quarter 2026 dividend

Fri, 17 Jul 2026 16:15:00 -0400

The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026.

Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026

Wed, 15 Jul 2026 16:15:00 -0400

NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Conference Call Information

Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website

Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026

Wed, 15 Jul 2026 16:15:00 -0400

Conference Call Information

Royalty Pharma (RPRX) PT Raised to $65 at TD Cowen

Mon, 13 Jul 2026 08:49:56 -0400

TD Cowen analyst Steve Scala raised the price target on Royalty Pharma (NASDAQ: RPRX) to $65.00 (from $50.00) while maintaining a rating.

Form 4 Royalty Pharma plc For: Jul 01 Filed by: Urist Marshall

Thu, 02 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260702/26727796.html

Form 4 Royalty Pharma plc For: Jul 01 Filed by: Urist Marshall

Thu, 02 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260702/26727796.html

Form 4 Royalty Pharma plc For: Jun 30 Filed by: Hite Christopher

Thu, 02 Jul 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260702/26727716.html

Form 4 Royalty Pharma plc For: Jun 30 Filed by: Hite Christopher

Thu, 02 Jul 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260702/26727716.html

Form 144 Royalty Pharma plc Filed by: Urist Marshall

Wed, 01 Jul 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260701/26720951.html

Form 144 Royalty Pharma plc Filed by: Urist Marshall

Wed, 01 Jul 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260701/26720951.html

Form 144 Royalty Pharma plc Filed by: SCH Investment Partners LLC

Wed, 01 Jul 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260701/26717335.html

Form 144 Royalty Pharma plc Filed by: SCH Investment Partners LLC

Wed, 01 Jul 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260701/26717335.html

Form 4 Royalty Pharma plc For: Jun 30 Filed by: Bassler Bonnie L

Tue, 30 Jun 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260630/26714814.html

Form 4 Royalty Pharma plc For: Jun 30 Filed by: Bassler Bonnie L

Tue, 30 Jun 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260630/26714814.html

Form 4 Royalty Pharma plc For: Jun 24 Filed by: Urist Marshall

Thu, 25 Jun 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260625/26693443.html

Form 4 Royalty Pharma plc For: Jun 24 Filed by: Urist Marshall

Thu, 25 Jun 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260625/26693443.html

Form 4 Royalty Pharma plc For: Jun 23 Filed by: Hite Christopher

Thu, 25 Jun 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260625/26693419.html

Form 4 Royalty Pharma plc For: Jun 23 Filed by: Hite Christopher

Thu, 25 Jun 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260625/26693419.html

Form 144 Royalty Pharma plc Filed by: Urist Marshall

Wed, 24 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260624/26685678.html

Form 144 Royalty Pharma plc Filed by: Urist Marshall

Wed, 24 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260624/26685678.html